Core Insights - Greenhaven Associates disclosed a new position in Baxter International, acquiring approximately 6,288,349 shares for about $143.19 million, representing 2.77% of its $5.17 billion in reportable equity holdings as of September 30, 2025 [2][3][8] Company Overview - Baxter International offers a diversified portfolio of healthcare products, including dialysis therapies, infusion systems, injectable drugs, anesthesia, surgical devices, and connected care technologies, serving healthcare providers in approximately 100 countries [4][5] - The company generates revenue primarily through the sale of medical devices, pharmaceuticals, and related services [4] Financial Performance - As of November 3, 2025, Baxter's stock was priced at $18.21, down 49.1% over the past year, significantly underperforming the S&P 500 by 67.93 percentage points [3] - Baxter's revenue for the trailing twelve months (TTM) is $11.02 billion, with a net income of -$341 million, and a dividend yield of 3.78% [3] Investment Context - Baxter's stock has declined by 78.14% over the last five years, while the S&P 500 index has gained 91.37% during the same period [7] - Greenhaven's investment may indicate growing confidence in a potential turnaround under new CEO Andrew Hider, who is focusing on strengthening the balance sheet and targeting a three-times net leverage by the end of 2026 [8] - The company is also reducing dividends to save over $300 million in annual cash flow, which could improve investor sentiment if successful [8] Market Valuation - Baxter is currently trading at 9.3 times forward earnings, which is considered reasonable in the current overheated market [9]

Core Viewpoint - Rosen Law Firm is urging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to stock purchases made between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions that could result in underinfusion, overinfusion, or non-delivery of fluids [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. regarding a federal securities class action lawsuit, with a lead plaintiff deadline set for December 15, 2025 [2][5]. Group 1: Legal Action and Deadlines - Investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. - The deadline for seeking the role of lead plaintiff in the class action lawsuit is December 15, 2025 [2]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by making false or misleading statements regarding the Novum LVP, which suffered systemic defects leading to serious patient risks [5]. - Specific allegations include that Baxter was aware of multiple device malfunctions and injuries but failed to adequately address these issues, resulting in a heightened risk of product recalls and sales pauses [5]. Group 3: Impact on Stock Performance - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause on shipments and installations of the Novum LVP, causing the stock to drop by 22.4%, closing at $21.76 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific claims include that Baxter was aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5]. - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][3]. Allegations - The complaint states that Baxter failed to disclose systemic defects in the Novum LVP device, leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the device but did not take adequate remedial measures, leading to continued harm [3]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can choose to remain absent class members without participating in the case [5]. Company Background - Baxter International, Inc. is a global company that develops, manufactures, and markets medical products used in healthcare facilities [1].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to these defects but failed to implement adequate remedial measures [3]. - The lawsuit alleges that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Points - A class action securities lawsuit has been filed against Baxter International, Inc. for alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3] - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to serious patient risks, including underinfusion, overinfusion, and non-delivery of fluids [3] - Allegations include that Baxter was aware of multiple malfunctions and injuries but failed to implement adequate remedial measures, resulting in misleading statements about the product's safety and sales prospects [3] Company Details - Baxter International, Inc. is facing legal challenges due to claims of product defects in its Novum LVP, which could lead to significant financial repercussions for the company [3] - The lawsuit highlights the potential for Baxter to halt new sales of the Novum LVP and remove existing units from service, indicating a serious impact on the company's operations and reputation [3] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, emphasizing their experience and success in similar lawsuits [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by December 15, 2025 [4]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of its Novum IQ Large Volume Pump, which suffered systemic defects leading to serious patient risks [6]. Group 2: Allegations Against Baxter - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to continued harm [6]. - The allegations suggest that Baxter's statements about the product's safety, efficacy, and sales prospects were materially false and misleading, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has systemic defects leading to serious patient risks [3][4]. Summary by Sections Allegations - The complaint claims that Baxter's Novum LVP product experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were characterized as materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Participation in the case does not require appointment as lead plaintiff, and there are no costs or obligations for shareholders to register [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Points - The Gross Law Firm has issued a notice to shareholders of Baxter International, Inc. regarding a class action lawsuit related to the company's Novum LVP product, which allegedly has systemic defects leading to serious patient risks [1][2] - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, during which Baxter is accused of making materially false and misleading statements about the safety and efficacy of the Novum LVP [1] - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Allegations Summary - Baxter's Novum LVP product reportedly suffered from defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1] - The company was allegedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures, leading to continued harm [1] - Baxter's statements regarding the product's safety, efficacy, and sales prospects were claimed to be materially false and misleading, increasing the risk of customers withdrawing the product from service [1]